Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 47

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 47
---
, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending the list of Selling Shareholders to include the pledgee, transferee or other
successors in interest as Selling Shareholders under this prospectus. The Selling Shareholders also may transfer the ordinary shares
in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial
owners for purposes of this prospectus.

In connection with the sale
of our ordinary shares or interests therein, the Selling Shareholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the ordinary shares in the course of hedging the positions they assume.
The Selling Shareholders may also sell our ordinary shares short and deliver these securities to close out their short positions, or loan
or pledge the ordinary shares to broker-dealers that in turn may sell these securities. The Selling Shareholders may also enter into option
or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require
the delivery to such broker-dealer or other financial institution of ordinary shares offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

<div align='center'>23</div>

Each of the Selling Shareholders
reserves the right to accept and, together with their respective agents from time to time, to reject, in whole or in part, any proposed
purchase of ordinary shares to be made directly or through agents. We will not receive any of the proceeds from this offering; however,
we expect to receive approximately $12.26 million from the exercise of the IR/PR Warrants, assuming such IR/PR Warrants were exercised
in full, unless such IR/PR Warrants were exercised on a “cashless” basis.

The Selling Shareholders
and any underwriters, broker-dealers or agents that participate in the sale of the ordinary shares or interests therein may be “underwriters”
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of
the ordinary shares may be underwriting discounts and commissions under the Securities Act. Selling Shareholders who are “underwriters”
within the meaning of Section 2(